Prediction of the Risk of Hospital Deaths in Patients with Hospital-Acquired Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii Infection: A Multi-Center Study

References

• Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008;52(3):813–821. doi:10.1128/AAC.01169-0718070961
   PubMed Web of Science ®Google Scholar
• Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis. 2006;42(Suppl 2):S72–S81. doi:10.1086/49940516355320
   PubMed Web of Science ®Google Scholar
• Xia J, Zhang D, Xu Y, Gong M, Zhou Y, Fang X. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam. Int J Infect Dis. 2014;23:90–93. doi:10.1016/j.ijid.2014.01.01724726664
   PubMed Web of Science ®Google Scholar
• Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010;362(19):1804–1813. doi:10.1056/NEJMra090412420463340
   PubMed Web of Science ®Google Scholar
• Gaynes R, Edwards JR, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41(6):848–854. doi:10.1086/43280316107985
   PubMed Web of Science ®Google Scholar
• Chung DR, Song JH, Kim SH, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184(12):1409–1417. doi:10.1164/rccm.201102-0349OC21920919
   PubMed Web of Science ®Google Scholar
• Kwak YG, Choi JY, Yoo HM, et al. Validation of the Korean National Healthcare-associated Infections Surveillance System (KONIS): an intensive care unit module report. J Hosp Infect. 2017;96(4):377–384. doi:10.1016/j.jhin.2017.04.00328545827
   PubMed Web of Science ®Google Scholar
• Chen CT, Wang YC, Kuo SC, et al. Community-acquired bloodstream infections caused by Acinetobacter baumannii: a matched case-control study. J Microbiol Immunol Infect. 2018;51(5):629–635. doi:10.1016/j.jmii.2017.02.00428701266
   PubMedGoogle Scholar
• Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(10):3471–3484.17646423
   PubMed Web of Science ®Google Scholar
• Fu Q, Ye H, Liu S. Risk factors for extensive drug-resistance and mortality in geriatric inpatients with bacteremia caused by Acinetobacter baumannii. Am J Infect Control. 2015;43(8):857–860. doi:10.1016/j.ajic.2015.03.03325960385
   PubMed Web of Science ®Google Scholar
• Lee NY, Lee JC, Li MC, Li CW, Ko WC. Empirical antimicrobial therapy for critically ill patients with Acinetobacter baumannii bacteremia: combination is better. J Microbiol Immunol Infect. 2013;46(5):397–398. doi:10.1016/j.jmii.2013.03.00423632604
   PubMedGoogle Scholar
• Prates CG, Martins AF, Superti SV, et al. Risk factors for 30-day mortality in patients with carbapenem-resistant Acinetobacter baumannii during an outbreak in an intensive care unit. Epidemiol Infect. 2011;139(3):411–418. doi:10.1017/S095026881000123820513254
   PubMed Web of Science ®Google Scholar
• Fagon J, Chastre J, Domart Y, Trouillet J, Gibert CJ. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis. 1996;23(3):538–542.8879777
   PubMed Web of Science ®Google Scholar
• Caricato A, Montini L, Bello G, et al. Risk factors and outcome of Acinetobacter baumanii infection in severe trauma patients. Intensive Care Med. 2009;35(11):1964–1969. doi:10.1007/s00134-009-1582-519652951
   PubMed Web of Science ®Google Scholar
• Munier AL, Biard L, Legrand M, et al. Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. Int J Infect Dis. 2019;79:179–184. doi:10.1016/j.ijid.2018.11.37130529108
   PubMed Web of Science ®Google Scholar
• Taitt CR, Leski TA, Stockelman MG, et al. Antimicrobial resistance determinants in Acinetobacter baumannii isolates taken from military treatment facilities. Antimicrob Agents Chemother. 2014;58(2):767–781. doi:10.1128/AAC.01897-1324247131
   PubMed Web of Science ®Google Scholar
• Zarrilli R, Pournaras S, Giannouli M, Tsakris A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int J Antimicrob Agents. 2013;41(1):11–19. doi:10.1016/j.ijantimicag.2012.09.00823127486
   PubMed Web of Science ®Google Scholar
• Sader HS, Flamm RK, Jones RN. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). Diagn Microbiol Infect Dis. 2013;75(4):417–422. doi:10.1016/j.diagmicrobio.2013.01.00123514757
   PubMed Web of Science ®Google Scholar
• Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16(3):128–140. doi:10.1016/0196-6553(88)90053-32841893
   PubMed Web of Science ®Google Scholar
• Allegranzi B, Bagheri Nejad S, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet (London, England). 2011;377(9761):228–241. doi:10.1016/S0140-6736(10)61458-4
   PubMed Web of Science ®Google Scholar
• Bebell LM, Muiru AN. Antibiotic use and emerging resistance: how can resource-limited countries turn the tide? Glob Heart. 2014;9(3):347–358. doi:10.1016/j.gheart.2014.08.00925667187
   PubMedGoogle Scholar
• Lim C, Takahashi E, Hongsuwan M, et al. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. eLife. 2016;5. doi:10.7554/eLife.18082
   Web of Science ®Google Scholar
• Strich JR, Palmore TN. Preventing transmission of multidrug-resistant pathogens in the intensive care unit. Infect Dis Clin North Am. 2017;31(3):535–550.28687211
   PubMed Web of Science ®Google Scholar
• Kołpa M, Wałaszek M, Gniadek A, Wolak Z, Dobroś W. Incidence, microbiological profile and risk factors of healthcare-associated infections in intensive care units: a 10 year observation in a provincial hospital in Southern Poland. Int J Environ Res Public Health. 2018;15(1):112. doi:10.3390/ijerph15010112
   PubMed Web of Science ®Google Scholar
• Thom KA, Rock C, Jackson SS, et al. Factors leading to transmission risk of Acinetobacter baumannii. Crit Care Med. 2017;45(7):e633–e639. doi:10.1097/CCM.000000000000231828398924
   PubMed Web of Science ®Google Scholar
• Lin HS, Lee MH, Cheng CW, et al. Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Infect Dis. 2015;47(6):370–378. doi:10.3109/00365548.2014.995129
   PubMed Web of Science ®Google Scholar
• Rossi I, Royer S, Ferreira ML, et al. Incidence of infections caused by carbapenem-resistant Acinetobacter baumannii. Am J Infect Control. 2019;47(12):1431–1435. doi:10.1016/j.ajic.2019.07.00931399285
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Perbix W, Seifert H. Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis. 1999;28(1):59–66. doi:10.1086/51506710028073
   PubMed Web of Science ®Google Scholar
• Albrecht MC, Griffith ME, Murray CK, et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg. 2006;203(4):546–550. doi:10.1016/j.jamcollsurg.2006.06.01317000400
   PubMed Web of Science ®Google Scholar
• Joung MK, Kwon KT, Kang CI, et al. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J Infect. 2010;61(3):212–218. doi:10.1016/j.jinf.2010.06.01420600295
   PubMed Web of Science ®Google Scholar